UNSPSC 51451603: Fenbendazole

This classification denotes an antihelminthic agent with the molecular formula C15H13N3O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 621BVT9M36, chemically known as 2-benzimidazolecarbamic acid, 5-(phenylthio)-, methyl ester but generally known as fenbendazole, which bears US NIH Compound Identifier 3334. European Medicines Agency schedules Fenbendazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07541MIG.

UNSPSC 51451603 Fenbendazole is a Commodity code that carries a significant mismatch between its nominal scope and recent state and local procurement activity. The code nominally describes fenbendazole, an anthelmintic pharmaceutical active ingredient, yet the recent opportunities posted under it involve naloxone (an opioid antagonist) and safe drug deactivation systems with no clear connection to fenbendazole or its veterinary or human-health applications. State and local procurement offices appear to have tagged these opportunities with the fenbendazole code in error, suggesting the code does not reflect actual buying patterns in the state and local market. No active solicitations for fenbendazole itself appear in the recent opportunities block.

The one completed award in the block—Illinois Department of Public Health's piggyback pharmaceutical contract with Chartwell Rx LLC, awarded August 28, 2026, for $2,999,999.11 over 12 months plus two optional renewal years—involved doxycycline and ciprofloxacin tablets, not fenbendazole. Seminole County, Florida posted an IFB on June 30, 2026, for naloxone and drug deactivation systems with a July 26, 2023 response deadline (a date discrepancy in the source). Given the absence of genuine fenbendazole solicitations and the apparent mistagging of unrelated pharmaceutical categories under this code, activity under UNSPSC 51451603 does not support a pursue recommendation at this time.